RxDoctor Payments Data

Elias Shaheen, MD

Family Medicine · Naples, FLNPI 1639305972

Payments from drug & device makers

$1,984in general payments, 2019–2025

Across 119 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$273
  • Pfizer$224
  • GSK$213
  • Takeda Pharmaceuticals U.S.A., Inc.$173
  • Novo Nordisk$161
  • Amgen$159
  • plus $780 from 18 others

What the payments were for

  • Food & beverage$1,95498%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,984 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$121,056
Medicare patients
434
Services billed
1,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide203$230,840
MounjaroTirzepatide82$102,688
JardianceEmpagliflozin51$76,881
EliquisApixaban69$71,378
XareltoRivaroxaban60$68,103
TrulicityDulaglutide26$44,609
JanuviaSitagliptin Phosphate19$31,523
MyrbetriqMirabegron34$27,260
EntrestoSacubitril/Valsartan20$23,748
FarxigaDapagliflozin Propanediol16$20,511
Repatha SureclickEvolocumab20$17,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,597
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$12,751
Tresiba Flextouch U-200Insulin Degludec14$10,873
Praluent PenAlirocumab16$9,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$161$230,840203 claims
Lilly USA, LLCMounjaro, Trulicity$83$147,297108 claims
Boehringer IngelheimJardiance$28$76,88151 claims
PfizerEliquis$224$71,37869 claims
Johnson & JohnsonXarelto$83$68,10360 claims
GSKTrelegy Ellipta, Anoro Ellipta$213$27,34837 claims
Astellas Pharma US IncMyrbetriq$16$27,26034 claims
NovartisEntresto$22$23,74820 claims
AstraZenecaFarxiga$273$20,51116 claims
AbbVieLinzess, Synthroid$136$9,48158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →